Singapore, Nov. 13 -- BioArctic AB's partner Eisai has announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the treatment of early Alzheimer's disease. Japan is the second country, following the US, where the subcutaneous formulation of Leqembi has been launched.

Leqembi Pen was approved in Japan on September 16, 2026, and has now been included in Japan's National Health Insurance (NHI) Drug Price List. It is the first and only anti-amyloid treatment in Japan that enables at-home administration.

Leqembi Pen is administered using an autoinjector and provides patients with a once-weekly subcutaneous treatment option in addition to intravenous (IV) administration every two weeks in a medical...